ALNY - Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook
2023-11-02 08:05:05 ET
More on Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
- Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One
- Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback
- Alnylam downgraded at Oppenheimer ahead of key data readout
For further details see:
Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook